US-PAT-NO: 4004021

DOCUMENT-IDENTIFIER: US 4004021 A

TITLE: Cyclopentane derivatives

----- KWIC -----

Brief Summary Text - BSTX (1):

This invention relates to new cyclopentane derivatives, and in particular it

relates to new cyclopentane derivatives which are analogues of the naturally

occurring compounds known as prostaglandin F.sub.2 .alpha. and prostaglandin

E.sub.2, showing a similar spectrum of pharmacological properties and being

useful for similar purposes. The relative potency of the new compounds,

however, in respect of the particular pharmacological effects shown is

different from that of the above naturally occurring prostaglandins, and in

particular they are more potent as luteolytic agents than the corresponding

natural prostaglandins. That is to say, in general the prostaglandin F.sub.2

.alpha. analogues of the present invention are more potent than natural

prostaglandin F.sub.2 .alpha., and the prostaglandin E.sub.2 analogues of the

present invention are more potent than natural

prostaglandin E.sub.2. The new

compounds are, however, less potent as stimulants of uterine smooth muscle than

the corresponding natural prostaglandins F.sub.2 .alpha. and E.sub.2, and are

therefore more selective in respect of luteolytic activity than the natural

prostaglandins. The new compounds are therefore advantageous when used as

contraceptives, for the termination of pregnancy or for control of the oestrus

cycle, and are also useful as hypotensives or for the relief of bronchospasm, and as inhibitors of blood platelet aggregation or of gastric secretion. The new compounds of the invention are also useful for addition to semen intended for artificial insemination of domestic animals, the success rate of insemination being thereby increased, especially in pigs and cattle.

US-PAT-NO: 3953495

DOCUMENT-IDENTIFIER: US 3953495 A

TITLE: 16-Methylene PGE.sub.2

----- KWIC -----

Brief Summary Text - BSTX (50):

The new prostaglandin compounds of the present invention and their

cyclodextrin clathrates and non-toxic salts, possess the valuable

pharmacological properties typical of prostaglandins in a selective fashion

including, in particular, luteolytic activity, stimulatory activity on uterine

contraction and antinidatory activity in female mammals, hypotensive activity,

inhibitory activity on gastric acid secretion and gastric ulceration,

bronchodilator activity and stimulatory activity on intestinal contraction and

are useful in the control of oestrus in female mammals, in particular in

economically valuable domestic animals, e.g. ewes, mares and cows, for example,

in order to facilitate artificial insemination, in the induction of labour in

pregnant female mammals, including economically valuable domestic animals, e.g.

ewes, mares, cows and sows, in the procurement of abortion in pregnant female

mammals, in the prevention of pregnancy in female mammals, including bitches,

in the treatment of hypertension, in the treatment of gastric ulceration, in

the treatment of asthma, in the treatment of intestinal dyskinesia and

post-operative intestinal paralysis and in the prevention and treatment of

constipation. The compounds of this invention induce moderate cutaneous

inflammation upon topical application to the skin. This topical activity may

be indicated in the management of chronically recurrent skin diseases which may

respond to induced inflammation. In particular

16-methylene-PGF.sub.2.sub..alpha. is of value in the control of oestrus in

female mammals and in the induction of labour in pregnant female mammals,

16-methylene-PGF.sub.2.sub..alpha. and

16-methylene-PGF.sub.2.sub..alpha.

methyl ester are of value in the prevention of pregnancy in female mammals,

16-methylene-PGE.sub.2 methyl ester is of value in the prevention of pregnancy

and in the control of oestrus in female mammals, and in the treatment of

hypertension, gastric ulceration and asthma, and

16-methylene-PGF.sub.2.sub..alpha. and 16

-methylene-PGE.sub.2 methyl ester

are of value in the treatment of intestinal dyskinesia and post-operative

intestinal paralysis and in the prevention and treatment of constipation. For

example in laboratory screening tests:

US-PAT-NO: 3953495

DOCUMENT-IDENTIFIER: US 3953495 A

TITLE: 16-Methylene PGE.sub.2

----- KWIC -----

Brief Summary Text - BSTX (50):

The new prostaglandin compounds of the present invention and their

cyclodextrin clathrates and non-toxic salts, possess the valuable

pharmacological properties typical of prostaglandins in a selective fashion

including, in particular, luteolytic activity, stimulatory activity on uterine

contraction and antinidatory activity in female mammals, hypotensive activity,

inhibitory activity on gastric acid secretion and gastric ulceration,

bronchodilator activity and stimulatory activity on intestinal contraction and

are useful in the control of oestrus in female mammals, in particular in

economically valuable domestic animals, e.g. ewes, mares and cows, for example,

in order to facilitate artificial insemination, in the induction of labour in

pregnant female mammals, including economically valuable domestic animals, e.g.

ewes, mares, cows and sows, in the procurement of abortion in pregnant female

mammals, in the prevention of pregnancy in female mammals, including bitches,

in the treatment of hypertension, in the treatment of gastric ulceration, in

the treatment of asthma, in the treatment of intestinal dyskinesia and

post-operative intestinal paralysis and in the prevention and treatment of

constipation. The compounds of this invention induce moderate cutaneous

inflammation upon topical application to the skin. This topical activity may

be indicated in the management of chronically recurrent skin diseases which may

respond to induced inflammation. In particular

16-methylene-PGF.sub.2.sub..alpha. is of value in the control of oestrus in

female mammals and in the induction of labour in pregnant female mammals,

16-methylene-PGF.sub.2.sub..alpha. and

16-methylene-PGF.sub.2.sub..alpha.

methyl ester are of value in the prevention of pregnancy in female mammals,

16-methylene-PGE.sub.2 methyl ester is of value in the prevention of pregnancy

and in the control of oestrus in female mammals, and in the treatment of

hypertension, gastric ulceration and asthma, and

16-methylene-PGF.sub.2.sub..alpha. and 16

-methylene-PGE.sub.2 methyl ester

are of value in the treatment of intestinal dyskinesia and post-operative

intestinal paralysis and in the prevention and treatment of constipation. For

example in laboratory screening tests: